Monkey CD160 antigen(CD160) ELISA kit
- Known as:
- Monkey CD160 antigenic(CD160) Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- e09c1463
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Blue gene shanghai
- Gene target:
- Monkey CD160 antigen(CD160) ELISA kit
Related genes to: Monkey CD160 antigen(CD160) ELISA kit
- Gene:
- CD160 NIH gene
- Name:
- CD160 molecule
- Previous symbol:
- -
- Synonyms:
- BY55, NK1, NK28
- Chromosome:
- 1q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-10-02
- Date modifiied:
- 2016-10-05
Related products to: Monkey CD160 antigen(CD160) ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size'F 4_80 Antigen (mouse) Host Rat'F 4_80 Antigen (mouse) Host Rat(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit Related articles to: Monkey CD160 antigen(CD160) ELISA kit
- Aberrant activation of SHH signaling contributes to the progression of multiple malignancies, with KIF7 functioning as a critical mediator that regulates signal transduction from SMO to GLI transcription factors. However, the specific role of KIF7 in ccRCC has not been fully elucidated. In this study, we investigated the expression pattern, prognostic significance, functional role, and potential mechanisms of KIF7 in ccRCC. Analysis of TCGA-KIRC data demonstrated that KIF7 expression was significantly elevated in tumor tissues compared with adjacent normal tissues. High KIF7 expression was strongly associated with advanced pathological stage and poor overall survival. IHC performed on commercial tissue microarrays further confirmed increased KIF7 protein levels in ccRCC samples. Functional experiments in the 786-O cell line revealed that KIF7 overexpression markedly enhanced cell proliferation. Mechanistically, KIF7 overexpression activated the Wnt/β-catenin signaling pathway and upregulated downstream cell cycle regulators, including c-Myc and c-Jun. KIF7 expression was positively correlated with infiltration of CD4 + T cells, macrophages, and neutrophils. Moreover, it showed significant positive associations with immune checkpoint molecules PDCD1 and CD160. GSCA/GDSC-based drug sensitivity prediction suggested that high KIF7 expression was associated with increased predicted sensitivity to docetaxel and bleomycin, whereas no significant association was observed for I-BET-762. In conclusion, KIF7 plays a tumor-promoting role in ccRCC by enhancing proliferation, activating Wnt/β-catenin signaling. Additionally, it was associated with shaping the immune microenvironment. These findings highlight KIF7 as a potential prognostic biomarker and therapeutic target in ccRCC. - Source: PubMed
Publication date: 2026/06/28
Wang YaoWang Xiao-MingHuo DaWang Shi-BoLiu Qian-YiPang JingShen TaoCui DiZhao Wen-JuanLuo Qing-FengLi NanChen Ai-QunCui Ju - LARC patients exhibit heterogeneity in their response to total neoadjuvant therapy (TNT). This study aims to screen and identify plasma biomarkers associated with treatment response to TNT in patients with locally advanced rectal cancer (LARC) to predict pathological complete response (pCR). - Source: PubMed
Publication date: 2026/06/08
Zhu ZonglinWen KaizhenZou BaoyiKang YanhuaChen JingqingZhu BinFan LipingHuang Haobo - In addition to well-established immune checkpoints (ICs), such as CTLA-4, PD-1, PD-L1, increasing attention is being directed toward next-generation ICs, including TIM-3, Gal-9, LAG-3, BTLA, HVEM, and CD160. Single nucleotide polymorphisms (SNPs) within IC-related genes may contribute to dysregulation of inhibitory pathways and impair anti-tumor immune responses. This study aimed to evaluate the association between selected IC gene variants and susceptibility to bladder cancer (BC). - Source: PubMed
Publication date: 2026/06/12
Andrzejczak AnnaKrajewski WojciechJaskuła EmiliaChorbińska JoannaTomkiewicz AnnaMałkiewicz BartoszSzydełko TomaszKarabon Lidia - Decidual natural killer (dNK) cells constitute approximately 70% of first-trimester decidual leukocytes and play critical roles in immune tolerance, angiogenesis, and trophoblast invasion. Single-cell RNA sequencing has revealed substantial heterogeneity within the dNK population, identifying three major subsets-dNK1, dNK2, and dNK3-with distinct transcriptomic profiles and predicted functions. dNK3 Characteristics: dNK3 cells are characterized by a CD160KLRB1CD103CD39 surface phenotype, T-bet-high/Eomes-intermediate transcription factor profile, and phenotypic resemblance to intraepithelial type 1 innate lymphoid cells (ieILC1). These cells demonstrate the highest effector capacity among dNK subsets, producing multiple cytokines (CCL5, XCL1, IFN-γ, GM-CSF) following stimulation. Predicted ligand-receptor interactions include CCL5-CCR1 with extravillous trophoblasts, XCL1-XCR1 with dendritic cells, and inhibitory axes through KLRB1-CLEC2D and TIGIT-PVR. Notably, dNK3 abundance undergoes dynamic changes across gestation and shows distinct spatial distribution within decidual compartments. - Source: PubMed
Publication date: 2026/05/13
Liu LidanZhang ZhaoHuang QianyiLiu BoWu Hongbo - Triple-negative breast cancer is an aggressive and heterogeneous type of invasive breast cancer (BC) in which the cancer cells lack estrogen and progesterone receptors, as well as expression of the human epidermal growth factor 2 protein. This cancer tends to grow and spread faster than other BC subtypes, and is associated with a poor prognosis due to early visceral and neurological recurrences. Multidisciplinary management includes surgery, chemotherapy, radiation therapy, and immunotherapy with targeted immune checkpoint inhibitors (ICIs). The introduction of ICIs has improved outcomes in patients with TNBC, particularly in the metastatic and neoadjuvant settings. Despite these advances, a significant proportion of patients either do not respond to treatment or develop resistance to it. TNBC mortality remains high, underscoring the urgent need to identify novel prognostic and predictive biomarkers to overcome resistance to immunotherapy. Following a brief overview of the clinical features and established biomarkers of TNBC, the current review focuses on immune checkpoint proteins (ICPs) beyond PD-1 and PD-L1, and on the potential use of soluble ICPs rather than the well-established membrane-bound assays. These soluble ICPs are produced through the alternative splicing of messenger (m)RNA or the cleavage/shedding of membrane-bound proteins. This is followed by an overview of current treatment and novel predictive targets in TNBC. Additionally, the involvement of the B- and T-lymphocyte attenuator (BTLA)/herpes virus entry mediator (HVEM)/CD160 pathway and its role in the pathogenesis of BC and TNBC are reviewed, highlighting the potential use of BTLA and HVEM as biomarkers. - Source: PubMed
Publication date: 2026/05/20
Rapoport Bernardo LAnderson Ronaldvan Tonder DanielSmit TeresaRossouw Theresa MBenn Carol-AnnSteel Helen C